-
Product Insights
NewPrader-Willi Syndrome (PWS) – Drugs In Development, 2024
Empower your strategies with our Prader-Willi Syndrome (PWS) – Drugs In Development, 2024 report and make more profitable business decisions. Prader-Willi syndrome (PWS) is a rare congenital genetic disorder that results in a number of physical, mental, and behavioral problems. PWS is due to the lack of several genes on one of an individual’s two chromosome 15s. In the majority of cases, there is a deletion. In the remaining cases, the entire chromosome from the father is missing and there are...
-
Product Insights
NewFragile X Syndrome – Drugs In Development, 2024
Empower your strategies with our Fragile X Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Fragile X syndrome is a genetic condition that causes a range of developmental problems including learning disabilities and cognitive impairment. Fragile X syndrome is caused by a change in a gene called FMR1, and occurs both in males and females. Symptoms include delay in crawling, walking, or twisting; hyperactive or impulsive behavior; speech and language delay; and intellectual disability. The Fragile...
-
Product Insights
NewPolycystic Kidney Disease – Drugs In Development, 2024
Empower your strategies with our Polycystic Kidney Disease – Drugs In Development, 2024 report and make more profitable business decisions. Polycystic kidney disease (PKD) is a disorder in which clusters of cysts develop primarily within kidneys. PKD symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination, and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics. The Polycystic Kidney Disease drugs in development market research report provide...
-
Product Insights
NewAlpha-1 Antitrypsin Deficiency (A1AD) – Drugs In Development, 2024
Empower your strategies with our Alpha-1 Antitrypsin Deficiency (A1AD) – Drugs In Development, 2024 report and make more profitable business decisions. Alpha-antitrypsin deficiency is an inherited disease that occurs due to lack of alpha-1 antitrypsin (AAT), a protein that protects the lungs. Symptoms include shortness of breath and wheezing, lung infections, rapid heartbeat, weight loss and vision problems. Predisposing factors include smoking, exposure to dust, chemical fumes, and infections. The Alpha-1 Antitrypsin Deficiency (A1AD) drugs in development market research report provide...
-
Product Insights
NewCharcot-Marie-Tooth Disease – Drugs In Development, 2024
Empower your strategies with our Charcot-Marie-Tooth Disease – Drugs In Development, 2024 report and make more profitable business decisions. Charcot-Marie-Tooth disease (CMT) is a term for a group of inherited genetic disorders that affect the peripheral nerves, which connect the brain and spinal cord to the muscles and sensory organs. CMT causes progressive weakness, muscle wasting, and loss of sensation in the feet, legs, hands, and arms. It can also cause foot deformities such as high arches or flat feet. CMT...